Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥ 18 years
Ineligibility for participation in any Amgen-sponsored ongoing clinical study of the investigational product
Pathologically documented, locally-advanced and unresectable or metastatic Non Small-Cell Lung Cancer (NSCLC) with KRAS p.G12C mutation confirmed through molecular testing
Exhausted other standard of care options for locally advanced and unresectable or metastatic NSCLC disease including platinum-based combination chemotherapy and programmed cell death protein 1/programmed death-ligand 1 (PD 1/PD-L1) immunotherapy (unless medically contraindicated)
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
You may not be if
Mixed small-cell lung cancer or mixed NSCLC histology
Active brain metastases
Active hepatitis B or hepatitis C virus
Current active malignancy other than NSCLC
Currently or previously enrolled in a prior sotorasib study unless radiographic disease progression confirmed, able to remain on long term follow up of their original protocol and receives medical monitor approval
Female participants planning to become pregnant while on study through 7 days after the last dose of sotorasib
